A Prospective Cohort Study for Patients With Adrenal Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults, male or female aged 19 years or older
- newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma
Exclusion Criteria:
- previous or current history of adrenal diseases
- using oral or intravenous steroids
- history of major depressive disorder
- history of chronic alcoholics
- history of any cancer with suspicious adrenal metastasis
- those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Non-functioning adrenal incidentaloma
patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
|
|
|
Pheochromocytoma
patients who were diagnosed with pheochromocytoma biochemically or histologically
|
|
|
Primary aldosteronism
patients who were diagnosed with primary aldosteronism by saline loading test
|
|
|
Adrenal cushing syndrome
patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
|
|
|
Adrenocortical carcinoma
patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants in remission
Time Frame: Up to 10 years
|
Remission rate
|
Up to 10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication of adrenal disease
Time Frame: Up to 10 years
|
all complications including deaths
|
Up to 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Paraganglioma
- Adenoma
- Hyperaldosteronism
- Cushing Syndrome
- Pheochromocytoma
- Adrenocortical Carcinoma
- Adrenocortical Adenoma
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones
Other Study ID Numbers
Other Study ID Numbers
- 1801-010-911
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing Syndrome
-
NCT07350707Recruiting
-
NCT06131580Active, not recruitingEndogenous Cushing Syndrome
-
NCT06430528RecruitingAdrenal Insufficiency | Hypercortisolism | Endogenous Cushing Syndrome
-
NCT07282223CompletedCushing's Syndrome | Postoperative | Prediction | Glucocorticoid
-
NCT03575247CompletedAdrenal; Insufficiency Gluccorticoid-Induced | Cushing; Syndrome or Disease, Glucocorticoid-Induced
-
NCT07168122RecruitingCushing Syndrome | Adrenal Insufficiency | Healthy Adult
-
NCT06246357RecruitingHyperaldosteronism | Hypercortisolism | Cushing s Syndrome
-
NCT07350031CompletedAdrenal Incidentaloma | Hypercortisolism
-
NCT03364803RecruitingCushing Syndrome | Cushing's Disease | Cushing Disease
-
NCT05436639CompletedAutonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, Somatic
Clinical Trials on Hormone study and Imaging study
-
NCT04689529Active, not recruitingBreast Cancer | Surgery | Chemotherapy Effect | IMAGE
-
NCT00627614Completed
-
NCT03258060Terminated
-
NCT00385333CompletedMacular Degeneration | Diabetic Retinopathy | Mitochondria | Hippel-Landau Disease
-
NCT03686215Completed
-
NCT00828620TerminatedMetastatic Colorectal Cancer